TARA
Protara Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$284.66M
P/E Ratio
—
EPS
$-1.34
Beta
1.50
52W High
$7.82
52W Low
$2.77
50-Day MA
$5.50
200-Day MA
$5.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-64.19M |
| Operating Margin | 0.00% |
| Return on Equity | -31.60% |
| Return on Assets | -20.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.67 |
| Price-to-Book | 1.45 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $55.06M |
| Float | $47.43M |
| % Insiders | 2.09% |
| % Institutions | 79.15% |
Historical Volatility
HV 10-Day
45.80%
HV 20-Day
44.71%
HV 30-Day
50.38%
HV 60-Day
85.58%
HV Rank
6.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($25.71 target)
2
Strong Buy6
BuyData last updated: 4/30/2026